Antonio Giorgio, Presenter: Nothing to Disclose

Giorgio Calisti, Abstract Co-Author: Nothing to Disclose

Carmine Coppola, Abstract Co-Author: Nothing to Disclose

Ferdinando Scarano, Abstract Co-Author: Nothing to Disclose

Umberto Scognamiglio, Abstract Co-Author: Nothing to Disclose

Luca Montesarchio, Abstract Co-Author: Nothing to Disclose

Piero Gatti, Abstract Co-Author: Nothing to Disclose

Paolo Matteucci, Abstract Co-Author: Nothing to Disclose

Valentina Giorgio, Abstract Co-Author: Nothing to Disclose

To report 7 years results on radiofrequency ablation (RFA) of single hepatocellular carcinoma (HCC) and the accompanying main portal vein tumor thrombus (MPVTT) in patients with compensated liver cirrhosis.

From January 2005 to January 2012, among 3144 consecutive cirrhosis patients, 772 had HCC and MPVTT; of these, 70 had a single HCC with MPVTT. 48 patients (38 men; mean age 69 years) with 48 HCC nodules -3.7-5 cm in diameter- invading main portal trunk (MPT) underwent RFA. 22 matched patients (18 men; mean age 69 years) with 22 HCC nodules -3.6-4.8 cm in diameter- extending into the MPT, refused RFA and composed the control group. Efficacy of RFA was defined complete when both complete necrosis of HCC and complete re-canalization of the MPT and its branches were achieved.

1, 3, 5 and 7-year cumulative survival rates of treated patients were 62, 29, 18 and 5%, respectively. The 12-months cumulative survival rate of un-treated patients was 0%. The difference was statistically significant (p < 0.001; hazard ratio 2.88; 95% CI 1.57– 5.39). The disease-free survival rates in treated group were 52, 38, 35 and 23% at 1, 3, 5 and 7 year, respectively. No death occurred.

RFA of HCC and the accompanying MPVTT significantly prolongs long-term survival compared with no treatment. The procedure is safe and should be considered as a new and effective tool in the treatment of advanced HCC.

RFA of HCC and the accompanying MPVTT in patients with compensated liver cirrhosis significantly prolongs long-term survival compared with no treatment.

Giorgio, A, Calisti, G, Coppola, C, Scarano, F, Scognamiglio, U, Montesarchio, L, Gatti, P, Matteucci, P, Giorgio, V, Hepatocellular Carcinoma (HCC) Invading Portal Venous System in Cirrhosis: 7 Years Results of Percutaneous Radiofrequency Ablation of HCC and Main Portal Vein Tumor Thrombus (MPVTT).  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14011067.html